Gossamer Bio, Inc. (GOSS)

0.7100 +0.0137 (+1.97%) At close: 04:00PM EDT

Gossamer Bio, Inc.

3013 Science Park Road
Suite 200
San Diego, CA 92121
United States
858 684 1300
https://www.gossamerbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 135

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Faheem Hasnain	Co-Founder, CEO, President & Chairman	910.26k	N/A	1958
Mr. Bryan Giraudo	COO & CFO	708.09k	N/A	1975
Mr. Robert P. Smith	Chief Commercial Officer	135.79k	N/A	1969
Mr. Christian Waage	Executive Vice President of Technical Operations & Administration	583.16k	N/A	1967
Mr. Jeff Boerneke	General Counsel & Secretary	N/A	N/A	N/A
Ms. Deanna Weber	Senior Vice President of Human Resources	N/A	N/A	N/A
Dr. Richard Aranda M.D.	Chief Medical Officer	625.24k	N/A	1961
Mr. Mario Orlando	Senior Vice President of Commercial New Product Planning	N/A	N/A	N/A
Ms. Caryn L. Peterson	Executive Vice President of Regulatory Affairs	N/A	N/A	1959
Mr. Matt Cravets	Senior Vice President of Biometrics	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Corporate governance

Gossamer Bio, Inc.’s ISS governance QualityScore as of 29 April 2024 is 9. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.